Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vera Therapeutics Inc Cl A (NQ: VERA )

36.70 -0.14 (-0.38%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 444,747
Open 37.67
Bid (Size) 36.28 (1)
Ask (Size) 40.00 (1)
Prev. Close 36.84
Today's Range 36.19 - 37.96
52wk Range 9.240 - 50.78
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer
From Vera Therapeutics
Via GlobeNewswire

Performance

YTD
+135.11%
+135.11%
1 Month
+4.17%
+4.17%
3 Month
-5.14%
-5.14%
6 Month
+45.00%
+45.00%
1 Year
+126.82%
+126.82%

More News

Read More
Vera Therapeutics Appoints Christy J. Oliger to Board of Directors
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics: Q4 Earnings Insights
Via Benzinga
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Vera Therapeutics
Via GlobeNewswire
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
Via Benzinga
Wall Street Snaps Five-Week Winning Streak, Economic Growth Slows, Inflation Holds Steady In April: This Week In The Market
Via Benzinga
Topics Economy
Exposures Interest Rates
Nvidia Is Up 186% From A Year Ago, Yet These 7 Stocks Have More Than Doubled Their Returns Over The AI Chipmaker
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress
From Vera Therapeutics
Via GlobeNewswire
VERA Stock Earnings: Vera Therapeutics Misses EPS for Q1 2024
Via InvestorPlace
Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
Could This Stock Be the Next Biotech Buyout?
Via The Motley Fool
Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact
Via Benzinga
Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
Via Investor's Business Daily
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Why Rallybio Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress
From Vera Therapeutics
Via GlobeNewswire
VERA Stock Earnings: Vera Therapeutics Misses EPS for Q4 2023
Via InvestorPlace
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference
From Vera Therapeutics
Via GlobeNewswire
$10M Bet On ArriVent BioPharma? Check Out These 4 Stocks Insiders Are Buying
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.